Kawasaki H, Mukai K, Yajima S, Tanaka R, Takayama J, Takasaki Y, Ohira M
Department of Pediatrics, Kansai Medical University, Japan.
Med Pediatr Oncol. 1995 May;24(5):300-4. doi: 10.1002/mpo.2950240506.
Immunostaining for proliferating cell nuclear antigen (PCNA), a marker of cell proliferation, is being increasingly used to study the proliferative activity of tumors, and the PCNA labeling index has been correlated with the prognosis of several malignant neoplasms. Formalin-fixed, paraffin-embedded tissue specimens of 24 primary neuroblastomas were immunostained using an anti-PCNA monoclonal antibody and the PCNA index was calculated. Then the relationship between the PCNA index, prognosis, and various other factors was assessed, retrospectively. The mean PCNA index was 11.0%. Patients having tumors with a high PCNA index (> or = 11.0%) showed a significantly lower survival rate than those possessing tumors with a low PCNA index (P < 0.001). Moreover, the tumors showing N-myc amplification had a high mean PCNA index of 15.6%, while those without N-myc amplification had a low mean index of 1.7% (P < 0.01). The PCNA index was closely related to the prognosis of neuroblastoma and to N-myc amplification. It has the potential to be a useful prognostic indicator of the patients with neuroblastoma.
增殖细胞核抗原（PCNA）作为细胞增殖的标志物，其免疫染色越来越多地用于研究肿瘤的增殖活性，并且PCNA标记指数已与几种恶性肿瘤的预后相关。使用抗PCNA单克隆抗体对24例原发性神经母细胞瘤的福尔马林固定、石蜡包埋组织标本进行免疫染色，并计算PCNA指数。然后回顾性评估PCNA指数、预后及其他各种因素之间的关系。PCNA指数的平均值为11.0%。PCNA指数高（≥11.0%）的肿瘤患者的生存率显著低于PCNA指数低的肿瘤患者（P<0.001）。此外，显示N-myc扩增的肿瘤平均PCNA指数较高，为15.6%，而无N-myc扩增的肿瘤平均指数较低，为1.7%（P<0.01）。PCNA指数与神经母细胞瘤的预后及N-myc扩增密切相关。它有可能成为神经母细胞瘤患者有用的预后指标。
